Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial

NCT03198052 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT03198052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03198052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2017
Completion date
August 1, 2036
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, car-t cell, immunotherapy, lung cancer